Fig. 1 | Scientific Reports

Fig. 1

From: Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation

Fig. 1

Kaplan-Meier survival curves of PFS and OS in these three groups of tumor patients. (A) PFS in patients with pancreatic neuroendocrine tumors, non-pancreatic neuroendocrine tumors, and other tumors. (B) OS in patients with pancreatic neuroendocrine tumors, non-pancreatic neuroendocrine tumors, and other tumors. PFS, progression-free survival; OS, overall survival; mPFS, median progression-free survival; mOS, median overall survival.

Back to article page